Small molecule c-met inhibitor PHA665752: Effect on cell growth and motility in papillary thyroid carcinoma

Head and Neck

Volumn 30, Issue 8, 2008, Pages 991-1000

  Chattopadhyay, Chandrani ^a   El Naggar, Adel K ^a   Williams, Michelle D ^a   Clayman, Gary L ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

C met; Cell migration; Papillary thyroid carcinoma; PHA665752; Small molecule inhibitor

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CELL ASSAY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SPECIFICITY; GROWTH CURVE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

APOPTOSIS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INDOLES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; SULFONES; THYROID NEOPLASMS;

EID: 50249160548     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20816     Document Type: Article

References (24)

1. Al-Brahim N, Asa SL. Papillary thyroid carcinoma: an overview. Arch Pathol Lab Med 2006;130:1057-1062.
2. Mazzaferri EL. Thyroid carcinoma: papillary and follicular. In: Mazzaferri L, Samaan NA, editors. Endocrine tumors. Cambridge, MA: Blackwell Scientific Publications; 1993. pp 278-333.
3. American Cancer Society. Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007.
4. Oyama T, Ichimura E, Sano T, Kashiwabara K, Fukuda T, Nakajima T. c-Met expression of thyroid tissue with special reference to papillary carcinoma. Pathol Int 1998;48:763-768.
5. Ramirez R, Hsu D, Patel A, et al. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2000;53:635-644.
6. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991;10:2867-2878.
7. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996;148:225-232.
8. Amemiya H, Kono K, Itakura J, et al. c-Met expression in gastric cancer with liver metastasis. Oncology 2002;63:286-296.
9. Mukohara T, Civiello G, Davis IJ, et al. Inhibition of the met receptor in mesothelioma. Clin Cancer Res 2005;11:8122-8130.
10. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-1488.
11. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000;19:5582-5589.
12. Kaplan O, Firon M, Vivi A, Navon G, Tsarfaty I. HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells. Neoplasia 2000;2:365-377.
13. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-1729.
14. Erratum in Cancer Res 2006;66:5976.
15. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Metdependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-7355.
16. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006;103:2316-2321.
17. Watson GA, Zhang X, Stang MT, et al. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia 2006;8:949-955.
18. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005;11:2312-2319.
19. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309-325.
20. de Luca A, Arena N, Sena LM, Medico E. Met overex-pression confers HGF-dependent invasive phenotype to human thyroid carcinoma cells in vitro. J Cell Physiol 1999;180:365-371.
21. Chen BK, Ohtsuki Y, Furihata M, et al. Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage. Pathol Res Pract 1999;195:427-433.
22. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A 2001;98:247-252.
23. Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, Salgia R. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 2007;292:L1488-L1494.
24. Mineo R, Costantino A, Frasca F, et al. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology 2004;145:4355-4365.